Aligos Therapeutics Ownership 2024 | Who Owns Aligos Therapeutics Now?
Institutional Ownership
30.28%
Insider Ownership
20.07%
Retail Ownership
49.65%
Institutional Holders
48.00
Aligos Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 4.65% | 0.03% | 7,256,410 | 363,000 | 5.27% | 2,539,744 | Jun 30, 2024 |
| ECOR1 CAPITAL, LLC | 4.09% | 0.07% | 6,389,468 | - | - | 2,236,314 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 3.91% | 0.06% | 6,102,770 | - | - | 2,135,970 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.20% | 0.00% | 5,000,000 | 2,535,495 | 102.88% | 1,750,000 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 2.27% | 0.11% | 3,547,030 | - | - | 1,241,461 | Jun 30, 2024 |
| HHLR ADVISORS, LTD. | 2.00% | 0.03% | 3,121,689 | 1,215,498 | 63.77% | 1,092,591 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 1.33% | 0.01% | 2,076,400 | - | - | 726,740 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 1.06% | 0.06% | 1,650,000 | - | - | 577,500 | Jun 30, 2024 |
| VANGUARD GROUP INC | 1.02% | - | 1,595,359 | 582,292 | 57.48% | 558,376 | Jun 30, 2024 |
| VERSANT VENTURE MANAGEMENT, LLC | 0.93% | 0.66% | 1,457,937 | -862,444 | -37.17% | 510,278 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 0.81% | 0.10% | 1,260,000 | -370,000 | -22.70% | 441,000 | Jun 30, 2024 |
| UBS OCONNOR LLC | 0.64% | 0.02% | 1,000,000 | 500,000 | 100.00% | 350,000 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.53% | 0.00% | 829,485 | 171,490 | 26.06% | 289,000 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.52% | - | 816,029 | -331,698 | -28.90% | 285,610 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.49% | 0.00% | 768,839 | -39,421 | -4.88% | 269,094 | Jun 30, 2024 |
| PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 0.48% | 0.20% | 743,215 | - | - | 260,125 | Jun 30, 2024 |
| NEWTYN MANAGEMENT, LLC | 0.46% | 0.05% | 719,287 | -480,713 | -40.06% | 251,750 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.42% | 0.05% | 655,515 | - | - | 229,430 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.34% | 0.00% | 531,204 | 531,204 | 100.00% | 185,921 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.26% | - | 405,694 | 32,638 | 8.75% | 142,022 | Jun 30, 2024 |
Aligos Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 4.65% of the company's total share outstanding, currently valued at $2.54M. The top 10 institutional shareholders own together 24.46% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VERSANT VENTURE MANAGEMENT, LLC | 0.93% | 0.66% | 1,457,937 | -862,444 | -37.17% | 510,278 | Jun 30, 2024 |
| PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 0.48% | 0.20% | 743,215 | - | - | 260,125 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 2.27% | 0.11% | 3,547,030 | - | - | 1,241,461 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 0.81% | 0.10% | 1,260,000 | -370,000 | -22.70% | 441,000 | Jun 30, 2024 |
| ECOR1 CAPITAL, LLC | 4.09% | 0.07% | 6,389,468 | - | - | 2,236,314 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 3.91% | 0.06% | 6,102,770 | - | - | 2,135,970 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 1.06% | 0.06% | 1,650,000 | - | - | 577,500 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.42% | 0.05% | 655,515 | - | - | 229,430 | Jun 30, 2024 |
| NEWTYN MANAGEMENT, LLC | 0.46% | 0.05% | 719,287 | -480,713 | -40.06% | 251,750 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 4.65% | 0.03% | 7,256,410 | 363,000 | 5.27% | 2,539,744 | Jun 30, 2024 |
| HHLR ADVISORS, LTD. | 2.00% | 0.03% | 3,121,689 | 1,215,498 | 63.77% | 1,092,591 | Jun 30, 2024 |
| UBS OCONNOR LLC | 0.64% | 0.02% | 1,000,000 | 500,000 | 100.00% | 350,000 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 1.33% | 0.01% | 2,076,400 | - | - | 726,740 | Jun 30, 2024 |
| HARBOURVEST PARTNERS LLC | 0.01% | 0.00% | 18,783 | - | - | 6,574 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.20% | 0.00% | 5,000,000 | 2,535,495 | 102.88% | 1,750,000 | Jun 30, 2024 |
| ZULLO INVESTMENT GROUP, INC. | 0.01% | 0.00% | 13,000 | - | - | 4,550 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.34% | 0.00% | 531,204 | 531,204 | 100.00% | 185,921 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.02% | 0.00% | 35,644 | -9,227 | -20.56% | 12,475 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.53% | 0.00% | 829,485 | 171,490 | 26.06% | 289,000 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.18% | 0.00% | 284,233 | 284,233 | 100.00% | 99,482 | Jun 30, 2024 |
The largest Aligos Therapeutics shareholder by % of total assets is VERSANT VENTURE MANAGEMENT, LLC. The company owns 1.46M shares of Aligos Therapeutics (ALGS), representing 0.66% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.20% | 0.00% | 5,000,000 | 2,535,495 | 102.88% | 1,750,000 | Jun 30, 2024 |
| HHLR ADVISORS, LTD. | 2.00% | 0.03% | 3,121,689 | 1,215,498 | 63.77% | 1,092,591 | Jun 30, 2024 |
| VANGUARD GROUP INC | 1.02% | - | 1,595,359 | 582,292 | 57.48% | 558,376 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.34% | 0.00% | 531,204 | 531,204 | 100.00% | 185,921 | Jun 30, 2024 |
| UBS OCONNOR LLC | 0.64% | 0.02% | 1,000,000 | 500,000 | 100.00% | 350,000 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 4.65% | 0.03% | 7,256,410 | 363,000 | 5.27% | 2,539,744 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.18% | 0.00% | 284,233 | 284,233 | 100.00% | 99,482 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.53% | 0.00% | 829,485 | 171,490 | 26.06% | 289,000 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.03% | 0.00% | 50,000 | 50,000 | 100.00% | 17,500 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.03% | 0.00% | 46,476 | 38,454 | 479.36% | 16,267 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.26% | - | 405,694 | 32,638 | 8.75% | 142,022 | Jun 30, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.01% | - | 19,600 | 19,600 | 100.00% | 6,860 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.01% | 0.00% | 12,306 | 12,306 | 100.00% | 4,000 | Jun 30, 2024 |
| HIGHTOWER ADVISORS, LLC | 0.01% | - | 10,000 | 10,000 | 100.00% | 4,000 | Jun 30, 2024 |
| STATE STREET CORP | 0.07% | - | 107,123 | 9,700 | 9.96% | 37,493,000 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 5,500 | 5,500 | 100.00% | 1,925 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.01% | - | 18,706 | 82 | 0.44% | 6,547 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 677 | - | - | 237 | Jun 30, 2024 |
| MORGAN STANLEY | 0.00% | - | 3,300 | - | - | 1,155 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.02% | - | 31,383 | - | - | 10,984 | Jun 30, 2024 |
As of Jun 30 2024, Aligos Therapeutics's largest institutional buyer is ADAGE CAPITAL PARTNERS GP, L.L.C.. The company purchased 2.54M stocks of ALGS, valued at $1.75M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ALYESKA INVESTMENT GROUP, L.P. | - | - | - | -6,103,217 | -100.00% | - | Jun 30, 2024 |
| VERSANT VENTURE MANAGEMENT, LLC | 0.93% | 0.66% | 1,457,937 | -862,444 | -37.17% | 510,278 | Jun 30, 2024 |
| NEWTYN MANAGEMENT, LLC | 0.46% | 0.05% | 719,287 | -480,713 | -40.06% | 251,750 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 0.81% | 0.10% | 1,260,000 | -370,000 | -22.70% | 441,000 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.52% | - | 816,029 | -331,698 | -28.90% | 285,610 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -92,000 | -100.00% | - | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.02% | - | 29,881 | -80,780 | -73.00% | 10,458 | Jun 30, 2024 |
| BLACKROCK INC. | 0.15% | - | 227,406 | -76,349 | -25.14% | 79,592 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.49% | 0.00% | 768,839 | -39,421 | -4.88% | 269,094 | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -34,173 | -100.00% | - | Jun 30, 2024 |
| PROCYON ADVISORS, LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | - | - | - | -12,500 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 362 | -10,463 | -96.66% | 127 | Jun 30, 2024 |
| FINANCIAL ADVOCATES INVESTMENT MANAGEMENT | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| TOTAL CLARITY WEALTH MANAGEMENT, INC. | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| XTX TOPCO LTD | 0.02% | 0.00% | 35,644 | -9,227 | -20.56% | 12,475 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -1,104 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -298 | -100.00% | - | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.06% | - | 91,950 | -65 | -0.07% | 32,183,000 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Aligos Therapeutics's biggest institutional seller is ALYESKA INVESTMENT GROUP, L.P.. The company sold -6.10M shares of ALGS, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WOODLINE PARTNERS LP | 0.34% | 0.00% | 531,204 | 531,204 | 100.00% | 185,921 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.03% | 0.00% | 50,000 | 50,000 | 100.00% | 17,500 | Jun 30, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.01% | - | 19,600 | 19,600 | 100.00% | 6,860 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.01% | 0.00% | 12,306 | 12,306 | 100.00% | 4,000 | Jun 30, 2024 |
| HIGHTOWER ADVISORS, LLC | 0.01% | - | 10,000 | 10,000 | 100.00% | 4,000 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 5,500 | 5,500 | 100.00% | 1,925 | Jun 30, 2024 |
Aligos Therapeutics's largest new institutional shareholder by number of shares is WOODLINE PARTNERS LP, purchased 531.20K shares, valued at $185.92K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ALYESKA INVESTMENT GROUP, L.P. | - | - | - | -6,103,217 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -92,000 | -100.00% | - | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -34,173 | -100.00% | - | Jun 30, 2024 |
| PROCYON ADVISORS, LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | - | - | - | -12,500 | -100.00% | - | Jun 30, 2024 |
| FINANCIAL ADVOCATES INVESTMENT MANAGEMENT | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| TOTAL CLARITY WEALTH MANAGEMENT, INC. | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -1,104 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | - | - | - | -298 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
Aligos Therapeutics's largest sold out institutional shareholder by shares sold is ALYESKA INVESTMENT GROUP, L.P., sold -6.10M shares, valued at -, as of undefined.
Aligos Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| IndexIQ ETF Trust | 0.12% | 265,526 | - | - | Jan 31, 2024 |
| Federated Hermes Equity Funds | 0.06% | 1,077,655 | - | - | Jan 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.04% | 21,969 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.04% | 92,000 | - | - | Mar 28, 2024 |
| ETFis Series Trust I | 0.01% | 13,420 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 36,306 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 3,087 | - | - | Mar 31, 2024 |
| Humankind Benefit Corp | 0.00% | 103 | - | - | Dec 31, 2023 |
| Nushares ETF Trust | 0.00% | 27,883 | - | - | Jan 31, 2024 |
| VANGUARD HORIZON FUNDS | 0.00% | 69,638 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 535 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 988,471 | -272,649 | -21.62% | Mar 31, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 608,708 | - | - | Dec 31, 2023 |
| ETF Managers Trust | 0.00% | 13,489 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 321,922 | 94,963 | 41.84% | Feb 29, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 82,408 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 24,596 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 31,383 | - | - | Jan 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 12,577 | - | - | Jan 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 1,471 | - | - | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 81,873 | - | - | Feb 29, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,300 | - | - | Mar 31, 2024 |
| HARTFORD MUTUAL FUNDS II INC | 0.00% | 40,400 | - | - | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 7,600 | - | - | Mar 31, 2024 |
| North Square Investments Trust | 0.00% | 1,730 | - | - | Jan 31, 2024 |
| Global X Funds | 0.00% | 5,968 | - | - | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 346 | - | - | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 72,083 | - | - | Feb 29, 2024 |
| HC CAPITAL TRUST | 0.00% | 4,000 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 10,997 | - | - | Mar 28, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 864 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 4,100 | - | - | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 201 | - | - | Dec 31, 2023 |
| FIDELITY SALEM STREET TRUST | 0.00% | 156,158 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 452 | - | - | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 3,453 | - | - | Mar 31, 2024 |
| HARTFORD MUTUAL FUNDS INC/CT | 0.00% | 300,468 | - | - | Jan 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 71,368 | - | - | Feb 29, 2024 |
| RBB FUND, INC. | 0.00% | 3,134 | - | - | Feb 29, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 642 | - | - | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 112 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 7,827 | - | - | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 7,842 | - | - | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 3,255 | - | - | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 700 | - | - | Mar 28, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 125 | - | - | Feb 29, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 8,054 | - | - | Feb 29, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 21 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 2,308 | - | - | Jan 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 15,815 | - | - | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 43,561 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 3,340 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 2,931 | - | - | Jan 31, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 1,890 | - | - | Mar 31, 2024 |
| Brighthouse Funds Trust II | 0.00% | 8,308 | - | - | Mar 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 1,000 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 769 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 17,800 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 148 | - | - | Jan 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 2,328 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 71,598 | 7,619 | 11.91% | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 4,751 | - | - | Mar 31, 2024 |
| GOLDMAN SACHS TRUST | 0.00% | 11,346 | - | - | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 330 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 735 | - | - | Jan 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 7,153 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 1,862 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 2,664 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 3,431 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 2,599 | - | - | Mar 28, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 7,500 | - | - | Feb 29, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 34 | - | - | Jan 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 1,131 | - | - | Mar 31, 2024 |
| John Hancock Funds II | 0.00% | 2,442 | - | - | Feb 29, 2024 |
Aligos Therapeutics's largest mutual fund holder by % of total assets is "IndexIQ ETF Trust", owning 265.53K shares, compromising 0.12% of its total assets.
Aligos Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 48 | -5.88% |
| 31 Mar, 24 | 51 | 27.50% |
| 31 Dec, 23 | 40 | 11.11% |
| 30 Sep, 23 | 36 | -14.29% |
| 30 Jun, 23 | 42 | -10.64% |
| 31 Mar, 23 | 47 | 17.50% |
| 31 Dec, 22 | 40 | -13.04% |
| 30 Sep, 22 | 46 | -14.81% |
| 30 Jun, 22 | 54 | -28.95% |
| 31 Mar, 22 | 76 | 7.04% |
| 31 Dec, 21 | 71 | 4.41% |
| 30 Sep, 21 | 68 | 19.30% |
| 30 Jun, 21 | 57 | 9.62% |
| 31 Mar, 21 | 52 | 1.96% |
| 31 Dec, 20 | 51 | - |
As of 30 Jun 24, 48 institutions are holding Aligos Therapeutics's shares, representing a decrease of -5.88% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 47,289,231 | 2.33% |
| 31 Mar, 24 | 46,213,782 | 1.91% |
| 31 Dec, 23 | 45,349,618 | 76.22% |
| 30 Sep, 23 | 25,734,205 | -2.11% |
| 30 Jun, 23 | 26,288,771 | -3.87% |
| 31 Mar, 23 | 27,346,961 | 3.18% |
| 31 Dec, 22 | 26,503,043 | -4.06% |
| 30 Sep, 22 | 27,624,193 | -7.25% |
| 30 Jun, 22 | 29,783,580 | -6.36% |
| 31 Mar, 22 | 31,806,203 | -3.31% |
| 31 Dec, 21 | 32,893,479 | 5.40% |
| 30 Sep, 21 | 31,209,533 | 15.52% |
| 30 Jun, 21 | 27,016,737 | -0.04% |
| 31 Mar, 21 | 27,027,243 | -0.87% |
| 31 Dec, 20 | 27,265,716 | - |
Aligos Therapeutics (ALGS) has 47.29M shares outstanding as of 30 Jun 24, up 2.33% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 30.28% | 0.59% |
| 31 Mar, 24 | 71.92% | 0.66% |
| 31 Dec, 23 | 104.26% | 2.94% |
| 30 Sep, 23 | 59.55% | 1.59% |
| 30 Jun, 23 | 61.26% | 1.51% |
| 31 Mar, 23 | 63.73% | 1.65% |
| 31 Dec, 22 | 62.08% | 1.49% |
| 30 Sep, 22 | 64.60% | 1.33% |
| 30 Jun, 22 | 69.81% | 1.25% |
| 31 Mar, 22 | 74.82% | 1.10% |
| 31 Dec, 21 | 82.53% | 1.52% |
| 30 Sep, 21 | 73.61% | 1.43% |
| 30 Jun, 21 | 71.82% | 1.38% |
| 31 Mar, 21 | 72.20% | 0.96% |
| 31 Dec, 20 | 86.65% | - |
As of 30 Jun 24, Aligos Therapeutics is held by 30.28% institutional shareholders, representing a 0.59% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 17 | -29.17% |
| 31 Mar, 24 | 24 | 41.18% |
| 31 Dec, 23 | 17 | 240.00% |
| 30 Sep, 23 | 5 | -37.50% |
| 30 Jun, 23 | 8 | -63.64% |
| 31 Mar, 23 | 22 | 69.23% |
| 31 Dec, 22 | 13 | -13.33% |
| 30 Sep, 22 | 15 | -40.00% |
| 30 Jun, 22 | 25 | -43.18% |
| 31 Mar, 22 | 44 | 25.71% |
| 31 Dec, 21 | 35 | -23.91% |
| 30 Sep, 21 | 46 | 31.43% |
| 30 Jun, 21 | 35 | 20.69% |
| 31 Mar, 21 | 29 | -43.14% |
| 31 Dec, 20 | 51 | - |
17 institutional shareholders have increased their position in ALGS stock as of 30 Jun 24 compared to 24 in the previous quarter (a -29.17% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 13 | 160.00% |
| 31 Mar, 24 | 5 | -28.57% |
| 31 Dec, 23 | 7 | -30.00% |
| 30 Sep, 23 | 10 | -23.08% |
| 30 Jun, 23 | 13 | 18.18% |
| 31 Mar, 23 | 11 | -15.38% |
| 31 Dec, 22 | 13 | -18.75% |
| 30 Sep, 22 | 16 | -5.88% |
| 30 Jun, 22 | 17 | 6.25% |
| 31 Mar, 22 | 16 | - |
| 31 Dec, 21 | 16 | 60.00% |
| 30 Sep, 21 | 10 | -9.09% |
| 30 Jun, 21 | 11 | 22.22% |
| 31 Mar, 21 | 9 | - |
| 31 Dec, 20 | - | - |
13 institutional shareholders have reduced their position in ALGS stock as of 30 Jun 24 compared to 5 in the previous quarter (a 160.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 48 | -5.88% | 47,289,231 | 2.33% | 30.28% | 0.59% | 17 | -29.17% | 13 | 160.00% |
| 31 Mar, 24 | 51 | 27.50% | 46,213,782 | 1.91% | 71.92% | 0.66% | 24 | 41.18% | 5 | -28.57% |
| 31 Dec, 23 | 40 | 11.11% | 45,349,618 | 76.22% | 104.26% | 2.94% | 17 | 240.00% | 7 | -30.00% |
| 30 Sep, 23 | 36 | -14.29% | 25,734,205 | -2.11% | 59.55% | 1.59% | 5 | -37.50% | 10 | -23.08% |
| 30 Jun, 23 | 42 | -10.64% | 26,288,771 | -3.87% | 61.26% | 1.51% | 8 | -63.64% | 13 | 18.18% |
| 31 Mar, 23 | 47 | 17.50% | 27,346,961 | 3.18% | 63.73% | 1.65% | 22 | 69.23% | 11 | -15.38% |
| 31 Dec, 22 | 40 | -13.04% | 26,503,043 | -4.06% | 62.08% | 1.49% | 13 | -13.33% | 13 | -18.75% |
| 30 Sep, 22 | 46 | -14.81% | 27,624,193 | -7.25% | 64.60% | 1.33% | 15 | -40.00% | 16 | -5.88% |
| 30 Jun, 22 | 54 | -28.95% | 29,783,580 | -6.36% | 69.81% | 1.25% | 25 | -43.18% | 17 | 6.25% |
| 31 Mar, 22 | 76 | 7.04% | 31,806,203 | -3.31% | 74.82% | 1.10% | 44 | 25.71% | 16 | - |
| 31 Dec, 21 | 71 | 4.41% | 32,893,479 | 5.40% | 82.53% | 1.52% | 35 | -23.91% | 16 | 60.00% |
| 30 Sep, 21 | 68 | 19.30% | 31,209,533 | 15.52% | 73.61% | 1.43% | 46 | 31.43% | 10 | -9.09% |
| 30 Jun, 21 | 57 | 9.62% | 27,016,737 | -0.04% | 71.82% | 1.38% | 35 | 20.69% | 11 | 22.22% |
| 31 Mar, 21 | 52 | 1.96% | 27,027,243 | -0.87% | 72.20% | 0.96% | 29 | -43.14% | 9 | - |
| 31 Dec, 20 | 51 | - | 27,265,716 | - | 86.65% | - | 51 | - | - | - |
Aligos Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Aligos Therapeutics's stock was made by Hirth Peter on Feb 28 2024, selling 15,000 shares at $26.58 per share (valued at $398.70K).
Aligos Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 2 | - | - |
| Q2 2024 | 4 | - | - |
| Q1 2024 | 21 | 13 | 161.54% |
| Q4 2023 | 6 | - | - |
| Q3 2023 | 10 | - | - |
| Q1 2023 | 6 | - | - |
| Q3 2022 | 11 | - | - |
| Q2 2022 | 10 | 3 | 333.33% |
| Q1 2022 | 12 | - | - |
| Q4 2021 | 1 | - | - |
| Q2 2021 | 12 | 4 | 300.00% |
| Q4 2020 | 64 | 54 | 118.52% |
2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Aligos Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | - | - |
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | 2 | - | - |
| Q3 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q2 2021 | - | - | - |
| Q4 2020 | 6 | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Aligos Therapeutics's stocks.
ALGS Ownership FAQ
Who Owns Aligos Therapeutics?
Aligos Therapeutics is owned by institutional shareholders (30.28%), insiders (20.07%), and public (49.65%). The largest institutional shareholder of Aligos Therapeutics is ARMISTICE CAPITAL, LLC (4.65% of total shares) and the top mutual fund owner is IndexIQ ETF Trust (0.12% of total shares).
Who are the major institutional shareholders of Aligos Therapeutics?
Aligos Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, ECOR1 CAPITAL, LLC, DEEP TRACK CAPITAL, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., and VIVO CAPITAL, LLC. The top five shareholders own together 18.12% of the company's share outstanding.
How many Aligos Therapeutics shareholders are there?
As of Jun 2024, there are 48 institutional shareholders of Aligos Therapeutics.
What percentage of Aligos Therapeutics is owned by ARMISTICE CAPITAL, LLC?
ARMISTICE CAPITAL, LLC owns 7.26M shares of Aligos Therapeutics, representing 4.65% of the company's total shares outstanding, valued at $2.54M (as of Jun 2024).
What percentage of Aligos Therapeutics is owned by ECOR1 CAPITAL, LLC?
As of Jun 2024, ECOR1 CAPITAL, LLC holds 6.39M shares of Aligos Therapeutics (ALGS), compromising 4.09% of the company, valued at $2.24M.
What percentage of Aligos Therapeutics is owned by DEEP TRACK CAPITAL, LP?
DEEP TRACK CAPITAL, LP is the third largest holder of Aligos Therapeutics. The company owns 6.1M of the company's shares outstanding (worth $2.14M).